These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

133 related articles for article (PubMed ID: 11388170)

  • 1. Discordant carbapenem susceptibility in Methylobacterium species and its application as a method for phenotypic identification.
    Zaharatos GJ; Dascal A; Miller MA
    J Clin Microbiol; 2001 May; 39(5):2037-8. PubMed ID: 11388170
    [No Abstract]   [Full Text] [Related]  

  • 2. Comparative activity of carbapenem testing: the COMPACT study.
    Nordmann P; Picazo JJ; Mutters R; Korten V; Quintana A; Laeuffer JM; Seak JC; Flamm RK; Morrissey I;
    J Antimicrob Chemother; 2011 May; 66(5):1070-8. PubMed ID: 21393160
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Comparative evaluation of in vitro activities of carbapenems against gram-negative pathogens: Turkish data of COMPACT study].
    Korten V; Söyletir G; Yalçın AN; Oğünç D; Dokuzoğuz B; Esener H; Ulusoy S; Tünger A; Aygen B; Sümerkan B; Arman D; Dizbay M; Akova M; Hasçelik G; Eraksoy H; Başaran S; Köksal I; Bayramoğlu G; Akalın H; Sınırtaş M
    Mikrobiyol Bul; 2011 Apr; 45(2):197-209. PubMed ID: 21644063
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pharmacodynamic profiling of doripenem, imipenem and meropenem against prevalent Gram-negative organisms in the Asia-Pacific region.
    Kiratisin P; Keel RA; Nicolau DP
    Int J Antimicrob Agents; 2013 Jan; 41(1):47-51. PubMed ID: 23127484
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Assessing the pharmacodynamic profile of intravenous antibiotics against prevalent Gram-negative organisms collected in Colombia.
    Villegas MV; Briceno DF; Ruiz SJ; Furtado GH; Nicolau DP
    Braz J Infect Dis; 2011; 15(5):413-9. PubMed ID: 22230846
    [TBL] [Abstract][Full Text] [Related]  

  • 6. In vitro activities of three carbapenems against recent bacterial isolates from severely ill patients at Swedish hospitals.
    Fraenkel CJ; Ullberg M; Bernander S; Ericson E; Larsson P; Rydberg J; Törnqvist E; Melhus A
    Scand J Infect Dis; 2006; 38(10):853-9. PubMed ID: 17008228
    [TBL] [Abstract][Full Text] [Related]  

  • 7. In-vitro activity of new carbapenem antibiotics: comparative studies with meropenem, L-627 and imipenem against pathogenic Nocardia spp.
    Yazawa K; Mikami Y; Ohashi S; Miyaji M; Ichihara Y; Nishimura C
    J Antimicrob Chemother; 1992 Feb; 29(2):169-72. PubMed ID: 1506332
    [TBL] [Abstract][Full Text] [Related]  

  • 8. In vitro antibacterial activities of doripenem, imipenem, and meropenem against recent Streptococcus pneumoniae isolates.
    Baek JY; Ko KS; Kang CI; Song JH; Peck KR
    Diagn Microbiol Infect Dis; 2011 Nov; 71(3):297-300. PubMed ID: 21855246
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparative Activity of Carbapenem Testing (COMPACT) study in Germany.
    Valenza G; Seifert H; Decker-Burgard S; Laeuffer J; Morrissey I; Mutters R;
    Int J Antimicrob Agents; 2012 Mar; 39(3):255-8. PubMed ID: 22230334
    [TBL] [Abstract][Full Text] [Related]  

  • 10. In-vitro interactions of DX-8739, a new carbapenem, meropenem and imipenem with amikacin against multiresistant Pseudomonas aeruginosa.
    Giamarellos-Bourboulis EJ; Grecka P; Giamarellou H
    J Antimicrob Chemother; 1996 Aug; 38(2):287-91. PubMed ID: 8877544
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Gastrointestinal selective capacity of doripenem, meropenem, and imipenem for carbapenem-resistant gram-negative bacilli in treated patients with pneumonia.
    Apisarnthanarak A; Kiratisin P; Apisarnthanarak P; Mundy LM
    Infect Control Hosp Epidemiol; 2011 Apr; 32(4):410-1. PubMed ID: 21460501
    [No Abstract]   [Full Text] [Related]  

  • 12. Pneumococcal susceptibility to meropenem.
    Fuchs PC; Barry AL; Brown SD
    J Antimicrob Chemother; 1996 May; 37(5):1036-7. PubMed ID: 8737158
    [No Abstract]   [Full Text] [Related]  

  • 13. BO-2727, meropenem and imipenem disc diffusion susceptibility testing criteria.
    Barry AL; Fuchs PC
    J Antimicrob Chemother; 1995 Aug; 36(2):444-6. PubMed ID: 8522478
    [No Abstract]   [Full Text] [Related]  

  • 14. In vitro activity and killing effect of DX-8739, a new carbapenem, compared with those of meropenem and imipenem against multiresistant Pseudomonas aeruginosa.
    Giamarellos-Bourboulis EJ; Grecka P; Giamarellou H
    Antimicrob Agents Chemother; 1995 Mar; 39(3):731-4. PubMed ID: 7793881
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Antimicrobial activity of doripenem and other carbapenems against gram-negative pathogens from Korea.
    Lee H; Ko KS; Song JH; Peck KR
    Microb Drug Resist; 2011 Mar; 17(1):37-45. PubMed ID: 20950191
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pharmacodynamic profiling of intravenous antibiotics against prevalent Gram-negative organisms across the globe: the PASSPORT Program-Asia-Pacific Region.
    Roberts JA; Kwa A; Montakantikul P; Gomersall C; Kuti JL; Nicolau DP
    Int J Antimicrob Agents; 2011 Mar; 37(3):225-9. PubMed ID: 21168997
    [TBL] [Abstract][Full Text] [Related]  

  • 17. In vitro activity of doripenem and other carbapenems against contemporary Gram-negative pathogens isolated from hospitalised patients in the Asia-Pacific region: results of the COMPACT Asia-Pacific Study.
    Christiansen KJ; Ip M; Ker HB; Mendoza M; Hsu L; Kiratisin P; Chongthaleong A; Redjeki IS; Quintana A; Flamm R; Garcia J; Cassettari M; Cooper D; Okolo P; Morrissey I
    Int J Antimicrob Agents; 2010 Dec; 36(6):501-6. PubMed ID: 20869212
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Antibacterial activity of meropenem against gram-negative bacteria with a permeability defect and against staphylococci.
    Kitzis MD; Acar JF; Gutmann L
    J Antimicrob Chemother; 1989 Sep; 24 Suppl A():125-32. PubMed ID: 2808204
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Role of cephalosporinase in carbapenem resistance of clinical isolates of Pseudomonas aeruginosa.
    Zhou XY; Kitzis MD; Gutmann L
    Antimicrob Agents Chemother; 1993 Jun; 37(6):1387-9. PubMed ID: 8328794
    [TBL] [Abstract][Full Text] [Related]  

  • 20. In-vitro susceptibility of Haemophilus influenzae to meropenem compared with imipenem, five other beta-lactams, chloramphenicol and ciprofloxacin.
    Powell M; Seetulsingh P; Williams JD
    J Antimicrob Chemother; 1989 Sep; 24 Suppl A():175-81. PubMed ID: 2808206
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.